Literature DB >> 6159395

Generation of cytotoxic lymphocytes to syngeneic tumor by using co-stimulator (Interleukin 2).

G B Mills, V Paetkau.   

Abstract

Cytotoxic lymphocytes (CL) highly active against the syngeneic mastocytoma, P815, were generated from spleen cells of DBA mice cultured with co-stimulator (Interleukin 2) and P815. More CL activity was generated from spleen cells of P815 tumor-bearing mice than from spleen cells of normal mice. Thymus cells from tumor-bearing mice, however, did not produce increased CL activity. Most of the CL were Thy 1 and Ly 1 positive. The optimal culture conditions and kinetics were similar to those for the generation of allogeneic cytotoxic T lymphocytes. The cytotoxic activity against syngeneic P815 was similar in magnitude to the response of DBA spleen cells to allogeneic tumor lines and to the response of allogeneic CBA spleen cells to P815. Although CL generated from tumor-bearing mice did not lyse normal DBA cells, they did lyse, to a much lesser degree, a number of tumor cell lines other than the sensitizing P815. This nonspecific lysis was not H2 restricted nor was it restricted to tumors of lymphoid origin. Generation of nonspecific cytolytic activity was antigen independent, occurring in the presence of co-stimulator alone.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6159395

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

1.  Melphalan-mediated potentiation of antitumor immune responsiveness of immunosuppressed spleen cells from mice bearing a large MOPC-315 tumor.

Authors:  R C Bocian; S Ben-Efraim; S Dray; M B Mokyr
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

2.  An analysis of T lymphocyte subsets in tumour-transplanted mice on the basis of Lyt antigenic markers and functions.

Authors:  P K Lala; I F McKenzie
Journal:  Immunology       Date:  1982-12       Impact factor: 7.397

3.  Adoptive chemoimmunotherapy of a syngeneic murine lymphoma with long-term lymphoid cell lines expanded in T cell growth factor.

Authors:  T J Eberlein; M Rosenstein; P Spiess; R Wesley; S A Rosenberg
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

4.  Antigenic variation in cancer metastasis: immune escape versus immune control.

Authors:  V Schirrmacher; M Fogel; E Russmann; K Bosslet; P Altevogt; L Beck
Journal:  Cancer Metastasis Rev       Date:  1982       Impact factor: 9.264

5.  Antibodies of predetermined specificity against chemically synthesized peptides of human interleukin 2.

Authors:  A Altman; J M Cardenas; R A Houghten; F J Dixon; A N Theofilopoulos
Journal:  Proc Natl Acad Sci U S A       Date:  1984-04       Impact factor: 11.205

6.  Methods for amplifying the induction and expression of cytotoxic response in vitro to syngeneic and autologous freshly-isolated solid tumors of mice.

Authors:  E Kedar; E Chriqui-Zeira; S Mitelman
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

7.  Interleukin 2 activity in peripheral blood mononuclear cells of patients with gynecologic malignancies.

Authors:  Y Kikuchi; T Kita; K Oomori; M Miyauchi; I Iwano; I Kizawa
Journal:  Med Oncol Tumor Pharmacother       Date:  1988

Review 8.  Interleukin-2 in cancer treatment: disappointing or (still) promising? A review.

Authors:  R A Maas; H F Dullens; W Den Otter
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

9.  In vivo modulation of thymus-derived lymphocytes with monoclonal antibodies in mice. III. Spontaneous and natural cytotoxic effector cells.

Authors:  A G Herbert; G S Le Gros; S Bidawid; J D Watson
Journal:  Immunology       Date:  1984-02       Impact factor: 7.397

10.  Splenocytes from tumor-bearing Corynebacterium parvum treated mice maintain interleukin-2 and -3 activity.

Authors:  A M Roberson; K D Elgert
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.